Mechanisms of a Mycobacterium tuberculosis Active Peptide

Author:

Rao Komal Umashankar1,Li Ping2,Welinder Charlotte3ORCID,Tenland Erik1,Gourdon Pontus24,Sturegård Erik5,Ho James C. S.6ORCID,Godaly Gabriela1ORCID

Affiliation:

1. Department of Microbiology, Immunology and Glycobiology, Institution of Laboratory Medicine, Lund University, SE-22362 Lund, Sweden

2. Department of Experimental Medical Science, Lund University, SE-22362 Lund, Sweden

3. Swedish National Infrastructure for Biological Mass Spectrometry, Lund University, SE-22362 Lund, Sweden

4. Department of Biomedical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark

5. Department of Clinical Microbiology, Institution of Translational Medicine, Lund University, SE-21428 Malmö, Sweden

6. Singapore Centre on Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University, Singapore 637553, Singapore

Abstract

Multidrug-resistant tuberculosis (MDR) continues to pose a threat to public health. Previously, we identified a cationic host defense peptide with activity against Mycobacterium tuberculosis in vivo and with a bactericidal effect against MDR M. tuberculosis at therapeutic concentrations. To understand the mechanisms of this peptide, we investigated its interactions with live M. tuberculosis and liposomes as a model. Peptide interactions with M. tuberculosis inner membranes induced tube-shaped membranous structures and massive vesicle formation, thus leading to bubbling cell death and ghost cell formation. Liposomal studies revealed that peptide insertion into inner membranes induced changes in the peptides’ secondary structure and that the membranes were pulled such that they aggregated without permeabilization, suggesting that the peptide has a strong inner membrane affinity. Finally, the peptide targeted essential proteins in M. tuberculosis, such as 60 kDa chaperonins and elongation factor Tu, that are involved in mycolic acid synthesis and protein folding, which had an impact on bacterial proliferation. The observed multifaceted targeting provides additional support for the therapeutic potential of this peptide.

Funder

Swedish Heart–Lung Foundation and King Oscar II’s anniversary fund

Alfred Österlund Foundation

Royal Physiographic Society of Lund

Swedish Research Council

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference52 articles.

1. Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399, 629–655.

2. Tolerance and Persistence to Drugs: A Main Challenge in the Fight Against Mycobacterium tuberculosis;Boldrin;Front. Microbiol.,2020

3. WHO (2023, January 04). Available online: https://www.who.int/news/item/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis.

4. Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance;Zignol;N. Engl. J. Med.,2016

5. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis;Bloemberg;N. Engl. J. Med.,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3